Dengke Teng1, Lei Ding2, Yu Wang3, Caimei Liu3, Yongxu Xia3, Hui Wang4. 1. Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130000, China. 2. Department of Radiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130000, China. 3. Department of Interventional Ultrasound, the 208th Hospital of PLA, Changchun, Jilin, 130000, China. 4. Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130000, China. 35985006@qq.com.
Abstract
PURPOSE: To evaluate the safety and efficiency of microwave ablation (MWA) with low power of 20 w, respectively, in the treatment of cervical metastatic lymph node (CMLN) from papillary thyroid carcinoma (PTC) with a mean of 32-month follow-up. METHODS: Eleven patients in total with 24 cervical lymph nodes (LNs) diagnosed with CMLN from PTC underwent MWA at a power of 20 w. We recorded images of the LNs under ultrasound first before MWA and 1, 3, 6, 12, months after MWA, and then every 6 months, respectively. The volumes of the LNs were compared before MWA and at each follow-up point after MWA. The thyroglobulin (Tg) test was performed before MWA and 3 months after MWA. RESULTS: All patients were successfully treated, and they showed no major complications. Before MWA, the mean volume of the LNs was 364.15 ± 306.89 mm3, which decreased to 234.10 ± 230.34 mm3, 107.51 ± 129.47 mm3, 20.88 ± 39.27 mm3, 3.38 ± 12.74 mm3, and completely disappeared at the follow-up point of 1, 3, 6, 12, and 18 months after MWA, respectively. The mean Tg was 11.81 ± 7.50 ng/ml, a data significantly decreased to 0.43 ± 0.11 ng/ml 3 months after MWA (P = 0.000). In the follow-up period, no recurrent lesions were found. CONCLUSIONS: For the treatment of CMLN from PTC, low power MWA showed good safety and efficacy. MWA is likely to be a candidate for patients with high risks or who refuse reoperation.
PURPOSE: To evaluate the safety and efficiency of microwave ablation (MWA) with low power of 20 w, respectively, in the treatment of cervical metastatic lymph node (CMLN) from papillary thyroid carcinoma (PTC) with a mean of 32-month follow-up. METHODS: Eleven patients in total with 24 cervical lymph nodes (LNs) diagnosed with CMLN from PTC underwent MWA at a power of 20 w. We recorded images of the LNs under ultrasound first before MWA and 1, 3, 6, 12, months after MWA, and then every 6 months, respectively. The volumes of the LNs were compared before MWA and at each follow-up point after MWA. The thyroglobulin (Tg) test was performed before MWA and 3 months after MWA. RESULTS: All patients were successfully treated, and they showed no major complications. Before MWA, the mean volume of the LNs was 364.15 ± 306.89 mm3, which decreased to 234.10 ± 230.34 mm3, 107.51 ± 129.47 mm3, 20.88 ± 39.27 mm3, 3.38 ± 12.74 mm3, and completely disappeared at the follow-up point of 1, 3, 6, 12, and 18 months after MWA, respectively. The mean Tg was 11.81 ± 7.50 ng/ml, a data significantly decreased to 0.43 ± 0.11 ng/ml 3 months after MWA (P = 0.000). In the follow-up period, no recurrent lesions were found. CONCLUSIONS: For the treatment of CMLN from PTC, low power MWA showed good safety and efficacy. MWA is likely to be a candidate for patients with high risks or who refuse reoperation.
Authors: Ji-hoon Kim; Won Sang Yoo; Young Joo Park; Do Joon Park; Tae Jin Yun; Seung Hong Choi; Chul-Ho Sohn; Kyu Eun Lee; Myung-Whun Sung; Yeo-Kyu Youn; Kwang Hyun Kim; Bo Youn Cho Journal: Radiology Date: 2015-04-03 Impact factor: 11.105
Authors: Waleed Shady; Elena N Petre; Kinh Gian Do; Mithat Gonen; Hooman Yarmohammadi; Karen T Brown; Nancy E Kemeny; Michael D'Angelica; Peter T Kingham; Stephen B Solomon; Constantinos T Sofocleous Journal: J Vasc Interv Radiol Date: 2017-12-06 Impact factor: 3.464
Authors: Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini Journal: Eur Thyroid J Date: 2021-05-25